Drug Approval | March 09, 2024
Dishman Carbogen Amcis updates on USFDA inspection at its Bavla facility
The inspection was concluded with few procedural observations
The inspection was concluded with few procedural observations
The company will provide comprehensive response to USFDA for the observations
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis
The validations confirm the completion of the applications and commence the scientific review process
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
ANVISA issues CGMP to Concord Biotech’s Unit I
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Subscribe To Our Newsletter & Stay Updated
